Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 11/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607432 | 1.00 | REN (0.49) | RENCYP3A4ANO1USP30STS | |
| SCHEMBL3607433 | 1.00 | REN (0.49) | RENCYP3A4ANO1USP30STS | |
| SCHEMBL4970583 | 0.90 | REN (0.49) | RENCYP3A4 | |
| SCHEMBL4970568 | 0.90 | REN (0.49) | RENCYP3A4 | |
| SCHEMBL2326044 | 0.88 | REN (0.57) | RENCYP3A4ANO1USP30STS | |
| SCHEMBL2326055 | 0.88 | REN (0.57) | RENCYP3A4ANO1USP30STS | |
| SCHEMBL2326048 | 0.88 | REN (0.57) | RENCYP3A4ANO1USP30STS | |
| SCHEMBL8229256 | 0.88 | REN (0.47) | RENCYP3A4ANO1USP30STS | |
| SCHEMBL9914196 | 0.88 | REN (0.49) | RENCYP3A4ANO1USP30STS | |
| SCHEMBL12090947 | 0.87 | REN (0.54) | RENCYP3A4ANO1USP30STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-1966139-B1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20100048636-A1 | Aspartic Protease Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| EP-1966139-A1 | ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007070201-A1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048636-A1 | Aspartic Protease Inhibitors | DNPEP, PEPD, SERPINB1 | REN 180/4885CYP3A4 2510/4885ANO1 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.